Dr. Giulia Monticone received her B.S. and M.S. at the University of Pavia (Italy), studying signaling pathways involved in cancer biology, followed by a Ph.D. from the University of Manchester (UK), where she investigated the post-translational regulation of intracellular signaling networks relevant to cancer progression and immune regulation. She completed her postdoctoral training at LSU Health Sciences Center (LSUHSC), specializing in immunosuppression and immunotherapy in the context of cancer and infections.
Dr. Monticone leads a research program focused on reversing disease-induced immunosuppression to restore protective immune responses and improve outcomes in cancer, infections and other immune-related conditions. Her work addresses: (1) Mechanisms of immunosuppression and immune dysregulation; (2) Computational drug discovery for immunotherapy; (3) Development of 3D organoid models to study immunoregulation and pre-clinical drug testing. Her research is supported by independent funding, including awards from the Department of Defense (DOD), National Institute of Health (NIH), American Association for Cancer Research (AACR) and the Center for Clinical and Translational Science (CCTS).
